Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Verdant Technologies LLC has 5 pending office actions in Biotechnology & Pharmaceuticals. The matters are handled by 3 examiners across 2 art units, showing some distribution while retaining a limited technical footprint.
SCHLIENTZ, NATHAN W is the busiest examiner, with 3 pending matters. The examiner carries a substantial share of the listed workload, making consistency in amendments and arguments especially useful for the related cases.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 2 (50%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, NATHAN W | 2 | 41.3% | -18.8% |
| DIAMOND, ALAN D | 1 | 71.5% | +8.5% |
| KOSACK, JOSEPH R | 1 | 74.8% | -6.1% |
| Art Unit | Apps |
|---|---|
| 1616 | 2 |
| 3991 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19539311 | COMPOSITIONS AND METHODS FOR DIFFERENTIAL RELEASE OF 1-METHYLCYCLOPROPENE | SCHLIENTZ, NATHAN W | 1616 | §103DP | Non-Final OA | — | Pending | Feb 13, 2026 |
| 18634437 | Electrostatic Printing of Cyclodextrin Compositions | DIAMOND, ALAN D | 3991 | §102 | Final Rejection | — | Pending | Apr 12, 2024 |
| 18125245 | CYCLODEXTRIN COMPOSITIONS, ARTICLES, AND METHODS | KOSACK, JOSEPH R | 3991 | §102 | Final Rejection | — | Pending | Mar 23, 2023 |
| 17232710 | COMPOSITIONS AND METHODS FOR DIFFERENTIAL RELEASE OF 1-METHYLCYCLOPROPENE | SCHLIENTZ, NATHAN W | 1616 | §103§112DP | Non-Final OA | — | Pending | Apr 16, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVerdant Technologies LLC has 4 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Nathan W Schlientz has the most, with 2 of Verdant Technologies LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
